| Symbol | LSTA |
|---|---|
| Name | LISATA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Misc Health and Biotechnology Services |
| Address | 110 ALLEN ROAD,2ND FLOOR, BASKING RIDGE, New Jersey, 07920, United States |
| Telephone | +1 908 842-0100 |
| Fax | — |
| — | |
| Website | https://www.lisata.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000320017 |
| Description | Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Additional info from NASDAQ: |
2026-06-09 11:30
(85% Positive) LISATA THERAPEUTICS, INC. (LSTA) Announces Business Combination
Read more
2026-06-09 08:31
New Form SC14D9C - LISATA THERAPEUTICS, INC. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001140361-26-024561 <b>Size:</b> 7 KB
Read more
2026-06-01 10:03
(85% Positive) LISATA THERAPEUTICS, INC. (LSTA) Announces Business Combination
Read more
2026-06-01 09:08
New Form SC TO-C - LISATA THERAPEUTICS, INC. <b>Filed:</b> 2026-06-01 <b>AccNo:</b> 0001140361-26-023433 <b>Size:</b> 38 KB
Read more
2026-06-01 07:09
New Form SC14D9C - LISATA THERAPEUTICS, INC. <b>Filed:</b> 2026-06-01 <b>AccNo:</b> 0001140361-26-023404 <b>Size:</b> 7 KB
Read more
2026-05-29 20:50
(90% Positive) LISATA THERAPEUTICS, INC. (LSTA) Announces Business Combination
Read more
2026-05-29 18:29
New Form SC TO-C - LISATA THERAPEUTICS, INC. <b>Filed:</b> 2026-05-29 <b>AccNo:</b> 0001140361-26-023355 <b>Size:</b> 53 KB
Read more
2026-05-29 18:00
New Form SC14D9C - LISATA THERAPEUTICS, INC. <b>Filed:</b> 2026-05-29 <b>AccNo:</b> 0001140361-26-023344 <b>Size:</b> 7 KB
Read more
2026-05-04 11:43
New Form SC TO-C - LISATA THERAPEUTICS, INC. <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001140361-26-018708 <b>Size:</b> 37 KB
Read more
2026-05-04 10:04
(85% Positive) LISATA THERAPEUTICS, INC. (LSTA) Announces Business Combination
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06592664 | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC | Phase1 | Pancreas Cancer | Withdrawn | 2030-01-01 | 2040-01-01 | ClinicalTrials.gov |
| NCT05712356 | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone i… | Phase2 | Cholangiocarcinoma | Terminated | 2023-05-13 | 2026-04-05 | ClinicalTrials.gov |
| NCT04990427 | CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Melli… | Phase1 | Chronic Kidney Diseases | Completed | 2022-01-10 | 2023-01-26 | ClinicalTrials.gov |
| NCT04614467 | A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dy… | Phase2 | Coronary Microvascular Dysfunction | Terminated | 2020-10-29 | 2022-09-28 | ClinicalTrials.gov |
| NCT04522817 | CLBS119 for Repair of COVID-19 Induced Pulmonary Damage | Phase1 | Covid-19 | Withdrawn | 2020-10-05 | 2021-05-01 | ClinicalTrials.gov |
| NCT03517176 | CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreat… | Phase1 | Pancreatic Cancer | Completed | 2018-07-31 | 2020-06-19 | ClinicalTrials.gov |
| NCT03508609 | Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascu… | Phase2 | Coronary Microvascular Dysfunction | Completed | 2018-04-19 | 2020-05-05 | ClinicalTrials.gov |
| NCT02501018 | Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Lim… | Phase2 | Critical Limb Ischemia | Completed | 2017-11-01 | 2022-05-19 | ClinicalTrials.gov |
| NCT02691247 | Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes … | Phase2 | Diabetes Mellitus | Completed | 2016-02-01 | 2020-01-01 | ClinicalTrials.gov |
| NCT01875653 | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma | Phase3 | Stage IV Melanoma | Terminated | 2014-10-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01508910 | Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cel… | Phase3 | Chronic Myocardial Ischemia | Completed | 2012-04-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01495364 | NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardi… | Phase2 | ST Segment Elevation Myocardial Infarction | Completed | 2011-12-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT00814593 | Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Ne… | Phase2 | Brain and Central Nervous System Tumors | Withdrawn | 2008-11-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00545610 | ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study) | — | Myocardial Ischemia | Completed | 2007-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00300053 | ACT34-CMI -- Adult Autologous CD34+ Cells | Phase2 | Myocardial Ischemia | Completed | 2006-04-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00014131 | Vaccine Therapy in Treating Patients With Kidney Cancer | Phase1 | Kidney Cancer | Terminated | 2001-11-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00012064 | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma | Phase1 | Melanoma (Skin) | Completed | 2000-07-01 | 2011-04-01 | ClinicalTrials.gov |
Total clinical trials: 17
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| FOLFOX regimen | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Gemcitabine | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Cisplatin | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Durvalumab | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| certepetide | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Placebo | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| FOLFOX regimen | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Gemcitabine | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Cisplatin | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Durvalumab | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| certepetide | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Placebo | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| FOLFOX regimen | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Gemcitabine | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Cisplatin | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Durvalumab | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| certepetide | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Placebo | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| FOLFOX regimen | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Gemcitabine | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Cisplatin | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Durvalumab | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| certepetide | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Placebo | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| FOLFOX regimen | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Gemcitabine | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Cisplatin | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Durvalumab | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| certepetide | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Placebo | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| FOLFOX regimen | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Gemcitabine | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Cisplatin | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Durvalumab | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| certepetide | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Placebo | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| FOLFOX regimen | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Gemcitabine | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Cisplatin | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Durvalumab | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| certepetide | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Placebo | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| FOLFOX regimen | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Gemcitabine | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Cisplatin | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Durvalumab | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| certepetide | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Placebo | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| FOLFOX regimen | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Gemcitabine | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Cisplatin | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Durvalumab | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| certepetide | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Placebo | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| FOLFOX regimen | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Gemcitabine | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Cisplatin | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Durvalumab | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| certepetide | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Placebo | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| FOLFOX regimen | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Gemcitabine | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Cisplatin | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Durvalumab | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| certepetide | Other | Phase PHASE2 | Cholangiocarcinoma | TERMINATED | NCT05712356 |
| Placebo | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| Placebo | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| Placebo | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| Placebo | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| Placebo | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| Placebo | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| Placebo | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| Placebo | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| Placebo | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| Placebo | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| Placebo | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS119 | Other | Phase PHASE1 | Covid-19 | WITHDRAWN | NCT04522817 |
| Placebo | Other | Phase PHASE2 | Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT05712356 |
| FOLFOX regimen | Other | Phase PHASE2 | Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT05712356 |
| Gemcitabine | Other | Phase PHASE2 | Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT05712356 |
| Cisplatin | Other | Phase PHASE2 | Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT05712356 |
| Durvalumab | Other | Phase PHASE2 | Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT05712356 |
| certepetide | Other | Phase PHASE2 | Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT05712356 |
| placebo | Other | Phase PHASE2 | ST Segment Elevation Myocardial Infarction | COMPLETED | NCT01495364 |
| NBS10 | Other | Phase PHASE2 | ST Segment Elevation Myocardial Infarction | COMPLETED | NCT01495364 |
| Standard of care | Other | Phase PHASE3 | Chronic Myocardial Ischemia | COMPLETED | NCT01508910 |
| Placebo: Diluent used to suspend Auto-CD34+ cells | Other | Phase PHASE3 | Chronic Myocardial Ischemia | COMPLETED | NCT01508910 |
| Auto-CD34+ cells | Other | Phase PHASE3 | Chronic Myocardial Ischemia | COMPLETED | NCT01508910 |
| Autologous PBMCs in GM-CSF (MC) | Other | Phase PHASE3 | Stage IV Melanoma | TERMINATED | NCT01875653 |
| Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC) | Drug | Phase PHASE3 | Stage IV Melanoma | TERMINATED | NCT01875653 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | COMPLETED | NCT03508609 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT02691247 |
| CLBS03 High Dose | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT02691247 |
| CLBS03 Low Dose | Other | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT02691247 |
| Placebo | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| CLBS16 | Other | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT03517176 |
| Nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT03517176 |
| CEND-1 | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT03517176 |
| CLBS201 | Other | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT04990427 |
| SOC | Other | Phase PHASE2 | Critical Limb Ischemia | COMPLETED | NCT02501018 |
| CLBS12 | Other | Phase PHASE2 | Critical Limb Ischemia | COMPLETED | NCT02501018 |
| placebo matching certepetide | DRUG | Phase PHASE1 | Pancreas Cancer | WITHDRAWN | NCT06592664 |
| gemcitabine | DRUG | Phase PHASE1 | Pancreas Cancer | WITHDRAWN | NCT06592664 |
| nab-paclitaxel | DRUG | Phase PHASE1 | Pancreas Cancer | WITHDRAWN | NCT06592664 |
| FOLFOX regimen | DRUG | Phase PHASE2 | Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT05712356 |
| Cisplatin | DRUG | Phase PHASE2 | Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT05712356 |
| Durvalumab | DRUG | Phase PHASE2 | Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT05712356 |
| certepetide | DRUG | Phase PHASE1 | Pancreas Cancer | WITHDRAWN | NCT06592664 |
| CLBS201 | DRUG | Phase PHASE1 | Chronic Kidney Diseases | COMPLETED | NCT04990427 |
| CLBS119 | BIOLOGICAL | Phase PHASE1 | Covid-19 | WITHDRAWN | NCT04522817 |
| Gemcitabine | DRUG | Phase PHASE2 | Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT05712356 |
| Nab-paclitaxel | DRUG | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT03517176 |
| CEND-1 | DRUG | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT03517176 |
| CLBS16 | BIOLOGICAL | Phase PHASE2 | Coronary Microvascular Dysfunction | TERMINATED | NCT04614467 |
| Placebo | DRUG | Phase PHASE2 | Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT05712356 |
| CLBS03 High Dose | BIOLOGICAL | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT02691247 |
| CLBS03 Low Dose | BIOLOGICAL | Phase PHASE2 | Diabetes Mellitus | COMPLETED | NCT02691247 |
| SOC | DRUG | Phase PHASE2 | Critical Limb Ischemia | COMPLETED | NCT02501018 |
| CLBS12 | BIOLOGICAL | Phase PHASE2 | Critical Limb Ischemia | COMPLETED | NCT02501018 |
| Autologous PBMCs in GM-CSF (MC) | BIOLOGICAL | Phase PHASE3 | Stage IV Melanoma | TERMINATED | NCT01875653 |
| Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC) | BIOLOGICAL | Phase PHASE3 | Stage IV Melanoma | TERMINATED | NCT01875653 |
| Standard of care | OTHER | Phase PHASE3 | Chronic Myocardial Ischemia | COMPLETED | NCT01508910 |
| Placebo: Diluent used to suspend Auto-CD34+ cells | BIOLOGICAL | Phase PHASE3 | Chronic Myocardial Ischemia | COMPLETED | NCT01508910 |
| Auto-CD34+ cells | BIOLOGICAL | Phase PHASE3 | Chronic Myocardial Ischemia | COMPLETED | NCT01508910 |
| placebo | OTHER | Phase PHASE2 | ST Segment Elevation Myocardial Infarction | COMPLETED | NCT01495364 |
| NBS10 | BIOLOGICAL | Phase PHASE2 | ST Segment Elevation Myocardial Infarction | COMPLETED | NCT01495364 |
| polifeprosan 20 with carmustine implant | DRUG | Phase PHASE2 | Brain and Central Nervous System Tumors | WITHDRAWN | NCT00814593 |
| lymphokine-activated killer cells | BIOLOGICAL | Phase PHASE2 | Brain and Central Nervous System Tumors | WITHDRAWN | NCT00814593 |
| placebo injection | BIOLOGICAL | Phase PHASE2 | Myocardial Ischemia | COMPLETED | NCT00300053 |
| CLBS14 (high-dose) | BIOLOGICAL | Phase PHASE2 | Myocardial Ischemia | COMPLETED | NCT00300053 |
| CLBS14 (low-dose) | BIOLOGICAL | Phase PHASE2 | Myocardial Ischemia | COMPLETED | NCT00300053 |
| Biological/Vaccine: therapeutic autologous dendritic cells. | BIOLOGICAL | Phase PHASE1 | Kidney Cancer | TERMINATED | NCT00014131 |
| therapeutic autologous dendritic cells | BIOLOGICAL | Phase PHASE1 | Melanoma (Skin) | COMPLETED | NCT00012064 |
Total products: 146